← Leaderboards
Drew Alexander Hall
University Of California, San Diego
$1,768,027
Attributed
$3,305,339
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $640.3K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,305,339 · 4
By mechanism
UG1$1,866,922 · 1
R21$1,438,417 · 3
Top collaborators
- Anthony John O'Donoghue3 shared
- Daniel M Werb3 shared
- Louise Chang Laurent2 shared
- Yu-Hwa Lo2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Louise Chang Laurent$25,039,144
- Peter John Davidson$7,709,517
- Daniel M Werb$3,258,461
- Anthony John O'Donoghue$3,220,387
- Tommi Lynn Gaines$4,336,355
Others in their field
Other Emerging Leaders on “Sampling”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,167,581
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Scott Topper · Broad Institute, Inc.$77,958,806
- Paul F Gallagher · Woods Hole Oceanographic Institution$63,916,876
- Leonard Freedman · Leidos Biomedical Research, Inc.$60,323,945
- Dale Sandler · Social And Scientific Systems, Inc.$59,740,435
Research focus
SamplingPoint Of CareBiosensorTechnologyValidationSignal TransductionPortabilitySurfaceMass Spectrum AnalysisLaboratoriesPerformanceAssay DevelopmentNanosensorsSensorHigh RiskDensityCostEnzymesInstrumentBiological MarkersMagnetic NanoparticlesMagnetismDevicesInfection
Grant awards (10)
Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats$608,483
UG1 · FY2025 · DA
Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats$618,092
UG1 · FY2024 · DA
Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats$640,347
UG1 · FY2023 · DA
Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease$197,396
R21 · FY2021 · EB
Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease$196,875
R21 · FY2020 · EB
Point-of-Care Quantitation of Sputum Neutrophil Elastase Activity in Chronic Airway Disease$236,250
R21 · FY2019 · EB
Magnetic nanosensors for real-time non-invasive biomarker detection in pregnancy$197,157
R21 · FY2019 · HD
Magnetic nanosensors for real-time non-invasive biomarker detection in pregnancy$235,729
R21 · FY2018 · HD
Point-of-Care Electrochemical Immunosignaturing$176,027
R21 · FY2018 · AI · contact PI
Point-of-Care Electrochemical Immunosignaturing$198,983
R21 · FY2017 · AI · contact PI